A patient with advanced pancreatic cancer lived 18 months without disease progression on an experimental drug. That data point, presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, drew a standing ovation from attending physicians. Why does this matter now? Because pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate below 10% and a median overall survival of less than one year for metastatic disease.
The Science Behind the Breakthrough
Daraxonrasib (formerly known as RMC-4630) is a potent and selective inhibitor of KRAS G12C, a specific mutation in the KRAS gene. KRAS is a mutated protein that drives tumor growth in several cancers, including pancreatic, lung, and colorectal. For decades, it was considered "undruggable" due to its smooth surface and lack of deep binding pockets. However, advances in medicinal chemistry allowed researchers to design molecules that covalently bind to the mutant cysteine, blocking oncogenic signaling.
In the phase 1/2 clinical trial, the patient—a 68-year-old man with metastatic pancreatic cancer who had progressed after first-line chemotherapy—received daraxonrasib combined with an SHP2 inhibitor (another protein involved in KRAS signaling). His tumor shrank by 30% per RECIST criteria and remained stable for a full 18 months. The median progression-free survival for metastatic pancreatic cancer is typically just 3 to 6 months with standard chemotherapy. This case represents a qualitative leap, especially considering the patient had exhausted conventional options.
“"A patient with advanced pancreatic cancer who did not progress for 18 months is something we have not seen before. This validates the strategy of inhibiting KRAS in this highly resistant tumor." — Dr. Manuel Hidalgo, pancreatic cancer specialist.”
Key Findings from the Case
- Durable Response: The patient maintained a partial response (≥30% tumor reduction) for 18 months, far exceeding expectations. Most responses to KRAS inhibitors in other tumors last between 6 and 12 months.
- Significant Tumor Shrinkage: Tumor size decreased by 30% following the combination treatment, with sustained improvement on follow-up imaging.
- Manageable Safety Profile: Side effects were primarily grade 1-2 (fatigue, nausea, diarrhea), with no severe toxicities requiring treatment discontinuation. No pneumonitis or severe hepatotoxicity was reported.
- Historical Context: No prior KRAS inhibitor has shown such prolonged activity in pancreatic cancer. Previous attempts with sotorasib and adagrasib in this tumor showed low response rates and short durations.
- Implications for Combination Therapy: The addition of an SHP2 inhibitor may have enhanced daraxonrasib's activity by preventing reactivation of the signaling pathway, a known resistance mechanism.
Why This Breakthrough Matters
Pancreatic cancer is notoriously resistant to chemotherapy and immunotherapy. Most patients are diagnosed at advanced stages when surgery is no longer an option. Therefore, any progress in targeted therapy is met with enthusiasm, but also skepticism due to past failures.
This case suggests that KRAS G12C inhibition, when strategically combined, could shift the paradigm. Although only a minority of pancreatic cancer patients harbor this mutation (around 1-2% in Caucasian populations, but up to 5% in certain subgroups), the success opens the door to combinations and next-generation drugs targeting other KRAS variants, such as G12D (present in ~40% of pancreatic cancers) and G12V (~30%).
Moreover, this result reinforces the importance of precision medicine: identifying the specific mutation in each patient's tumor can enable personalized treatments with unprecedented efficacy. The oncology community now eagerly awaits expansion cohort data, which will include more pancreatic cancer patients with G12C mutations.
Your Protocol: Evidence-Based Practical Steps
While this treatment is not yet approved by the FDA or EMA, you can take steps to stay informed and optimize your health, especially if you have risk factors:
- 1Know Your Genetic Risk: If you have a family history of pancreatic cancer (especially in first-degree relatives), consult a geneticist about testing for germline mutations like BRCA1/2, PALB2, and somatic mutations like KRAS. Early detection of mutations can open doors to clinical trials.
- 2Explore Clinical Trials: Platforms like ClinicalTrials.gov list active studies for daraxonrasib and other KRAS inhibitors. If you are a patient with advanced pancreatic cancer, ask your oncologist about eligibility for trials evaluating KRAS inhibitors in combination with other agents. The response rate in this case suggests that patients with G12C mutations could benefit significantly.
- 3Adopt Preventive Habits: Although genetics play a major role, modifiable risk factors include smoking (increases risk 2-3 times), obesity (BMI >30), long-standing type 2 diabetes, and heavy alcohol consumption. Maintaining a healthy weight, not smoking, and limiting alcohol reduce the risk of developing pancreatic cancer, as well as other tumors.
- 4Stay Informed About Biomarkers: If you undergo a liquid or tissue biopsy, ensure it includes a panel of KRAS mutations. Identifying G12C could be an opportunity to access investigational targeted therapies.
What To Watch Next
Revolution Medicines plans to expand trials to more patients and explore combinations with immunotherapy (such as PD-1 inhibitors) and chemotherapy. Data from other KRAS G12C inhibitors in development, such as adagrasib (Mirati Therapeutics) and sotorasib (Amgen), are also expected to show activity in pancreatic cancer if combined appropriately.
Moreover, researchers are developing KRAS G12D inhibitors, a much more common mutation in this cancer. Compounds like MRTX1133 (Mirati) and RMC-9805 (Revolution Medicines) are in early phases. If those drugs achieve similar results to daraxonrasib, we could be on the cusp of a new era in pancreatic cancer treatment.
Another key aspect is acquired resistance. Patients who initially respond to KRAS inhibitors often develop secondary mutations that reactivate the pathway. Combinations with SHP2, SOS1, or MEK inhibitors could delay or prevent that resistance. The coming years will be crucial to determine the durability of responses and optimal sequencing strategies.
The Bottom Line
One patient does not make a revolution, but when medicine has seen little progress in such an aggressive cancer for decades, every case counts. Daraxonrasib has shown it is possible to halt the disease for over a year in a context where progression is the norm. The next step is to confirm these results in larger studies and, hopefully, offer real hope to thousands of people facing a devastating diagnosis.
The combination of daraxonrasib with an SHP2 inhibitor represents a rational strategy that could be applied to other KRAS mutations. Meanwhile, the medical community watches with cautious optimism, knowing that the path from a successful case to a standard treatment is long, but this first step is promising.
